Small cell conversion complicated with hypertrophic pulmonary osteoarthropathy after targeted therapy for advanced EGFR-mutated lung adenocarcinoma: A case report
In recent years, with the opening of the era of precision therapy, the treatment of patients with positive driver genes is a hot issue in global research. EGFR is the most common driver gene in NSCLC, with a positivity rate of 17%. Although targeted drugs for EGFR mutations can benefit this populati...
Saved in:
Main Authors: | Sijia Zhang, Leichong Chen, Kuikui Zhu, Rui Meng |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2023-03-01
|
Series: | Indian Journal of Pathology and Microbiology |
Subjects: | |
Online Access: | https://journals.lww.com/10.4103/ijpm.ijpm_280_22 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and Safety of Chemotherapy or EGFR‐TKIs as First‐Line Therapy in NSCLC Patients Harboring Non‐Ex 20 Ins Uncommon EGFR Mutations: A Retrospective Study in China
by: Chen Liao, et al.
Published: (2025-01-01) -
EGFR-Mutated Lung Adenocarcinoma With Li–Fraumeni Syndrome: The Imperative for Germline Testing in Patients With a Family History, a Case Report
by: Hiroyuki Fujii, MD, et al.
Published: (2025-02-01) -
Solid Predominant Histology and High Podoplanin Expression in Cancer-Associated Fibroblast Predict Primary Resistance to Osimertinib in EGFR-Mutated Lung Adenocarcinoma
by: Yuji Uehara, MD, et al.
Published: (2025-03-01) -
Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors
by: Nathaniel J. Myall, MD, et al.
Published: (2025-02-01) -
Differential diagnosis of hypertrophic pachymeningitis: literature review
by: G. Makarevičius, et al.
Published: (2022-03-01)